Robin Reschke

842 total citations
31 papers, 390 citations indexed

About

Robin Reschke is a scholar working on Oncology, Immunology and Epidemiology. According to data from OpenAlex, Robin Reschke has authored 31 papers receiving a total of 390 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 15 papers in Immunology and 7 papers in Epidemiology. Recurrent topics in Robin Reschke's work include CAR-T cell therapy research (13 papers), Cancer Immunotherapy and Biomarkers (12 papers) and Immunotherapy and Immune Responses (11 papers). Robin Reschke is often cited by papers focused on CAR-T cell therapy research (13 papers), Cancer Immunotherapy and Biomarkers (12 papers) and Immunotherapy and Immune Responses (11 papers). Robin Reschke collaborates with scholars based in Germany, United States and Thailand. Robin Reschke's co-authors include Mirjana Ziemer, Thomas F. Gajewski, Jovian Yu, Jessica C. Hassel, Alexander Enk, Daniel J. Olson, Ken Hatogai, Emily F. Higgs, Blake Flood and Jan‐Christoph Simon and has published in prestigious journals such as International Journal of Molecular Sciences, Frontiers in Immunology and Trends in Immunology.

In The Last Decade

Robin Reschke

30 papers receiving 384 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Robin Reschke Germany 12 270 211 82 39 33 31 390
Kentaro Sumida Japan 9 295 1.1× 458 2.2× 100 1.2× 19 0.5× 23 0.7× 17 602
Megumi Aoki Japan 9 253 0.9× 122 0.6× 67 0.8× 73 1.9× 40 1.2× 27 349
Jong Myun Park United States 7 215 0.8× 393 1.9× 88 1.1× 17 0.4× 15 0.5× 7 505
Asuka Kobayashi Japan 9 172 0.6× 139 0.7× 125 1.5× 38 1.0× 13 0.4× 15 359
Helen Chae United States 3 245 0.9× 186 0.9× 186 2.3× 17 0.4× 12 0.4× 3 387
Yemsratch T. Akalu United States 5 65 0.2× 241 1.1× 70 0.9× 21 0.5× 24 0.7× 6 347
Christina Paluskievicz United States 9 174 0.6× 231 1.1× 122 1.5× 40 1.0× 27 0.8× 11 421
Xuexiao Jin China 8 132 0.5× 168 0.8× 143 1.7× 18 0.5× 25 0.8× 15 338
Anniek Zaalberg Netherlands 6 70 0.3× 134 0.6× 70 0.9× 47 1.2× 10 0.3× 9 259

Countries citing papers authored by Robin Reschke

Since Specialization
Citations

This map shows the geographic impact of Robin Reschke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robin Reschke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robin Reschke more than expected).

Fields of papers citing papers by Robin Reschke

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robin Reschke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robin Reschke. The network helps show where Robin Reschke may publish in the future.

Co-authorship network of co-authors of Robin Reschke

This figure shows the co-authorship network connecting the top 25 collaborators of Robin Reschke. A scholar is included among the top collaborators of Robin Reschke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robin Reschke. Robin Reschke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Reschke, Robin, Alexander Enk, & Jessica C. Hassel. (2025). Adiponectin to the rescue: extracorporeal photopheresis for managing immune checkpoint inhibitor-induced toxicities. Signal Transduction and Targeted Therapy. 10(1). 110–110. 1 indexed citations
2.
Koch, Vitali, Scherwin Mahmoudi, Christian Booz, et al.. (2024). Predictive Value of Dual-Energy CT-Derived Metrics for the Use of Bone Substitutes in Distal Radius Fracture Surgery. Diagnostics. 14(7). 697–697. 2 indexed citations
3.
Reschke, Robin, et al.. (2024). The role of tissue-resident memory T cells as mediators for response and toxicity in immunotherapy-treated melanoma—two sides of the same coin?. Frontiers in Immunology. 15. 1385781–1385781. 12 indexed citations
4.
Reschke, Robin, Ryan J. Sullivan, Evan J. Lipson, et al.. (2024). Targeting molecular pathways to control immune checkpoint inhibitor toxicities. Trends in Immunology. 46(1). 61–73. 15 indexed citations
5.
Enk, Alexander, et al.. (2024). Immune Checkpoints and Cellular Landscape of the Tumor Microenvironment in Non-Melanoma Skin Cancer (NMSC). Cells. 13(19). 1615–1615. 11 indexed citations
6.
Reschke, Robin, Alexander Enk, & Jessica C. Hassel. (2024). Prognostic Biomarkers in Evolving Melanoma Immunotherapy. American Journal of Clinical Dermatology. 26(2). 213–223. 8 indexed citations
7.
Reschke, Robin, Jörg Richter, Alexander Enk, & Jessica C. Hassel. (2024). Use of Anti-PD1 Blockade After Hedgehog Inhibitors or as First-Line Therapy for Gorlin Syndrome. JAMA Dermatology. 161(1). 104–104. 2 indexed citations
8.
Reschke, Robin, Alexander Enk, & Jessica C. Hassel. (2024). T Cell-Engaging Bispecific Antibodies Targeting gp100 and PRAME: Expanding Application from Uveal Melanoma to Cutaneous Melanoma. Pharmaceutics. 16(8). 1046–1046. 6 indexed citations
9.
Hofauer, Benedikt, Markus Wirth, Barbara Wollenberg, et al.. (2023). Novel Discovery of the Somatostatin Receptor (SSTR2) in Pleomorphic Adenomas via Immunohistochemical Analysis of Tumors of the Salivary Glands. Cancers. 15(15). 3917–3917. 2 indexed citations
10.
Keller, Laura, Christian Meß, Alexander T. Bauer, et al.. (2023). Prognostic value of von Willebrand factor levels in patients with metastatic melanoma treated by immune checkpoint inhibitors. Journal for ImmunoTherapy of Cancer. 11(5). e006456–e006456. 11 indexed citations
11.
Reschke, Robin & Thomas F. Gajewski. (2023). Tissue-resident memory T cells in immune-related adverse events: friend or foe?. OncoImmunology. 12(1). 2197358–2197358. 9 indexed citations
12.
Reschke, Robin, Jason W. Shapiro, Jovian Yu, et al.. (2022). Checkpoint Blockade–Induced Dermatitis and Colitis Are Dominated by Tissue-Resident Memory T Cells and Th1/Tc1 Cytokines. Cancer Immunology Research. 10(10). 1167–1174. 62 indexed citations
13.
14.
Reschke, Robin, Manfred Kunz, & Mirjana Ziemer. (2022). Gummatous cutaneous syphilis. Deutsches Ärzteblatt international. 119(26). 457–457. 1 indexed citations
15.
Reschke, Robin, Jovian Yu, Blake Flood, et al.. (2021). Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma. Journal for ImmunoTherapy of Cancer. 9(9). e003521–e003521. 98 indexed citations
16.
Reschke, Robin, et al.. (2021). Therapy understanding and health related quality of life in stage III/IV melanoma patients treated with novel adjuvant therapies. JDDG Journal der Deutschen Dermatologischen Gesellschaft. 19(2). 215–221. 4 indexed citations
17.
Reschke, Robin, et al.. (2021). Therapieverständnis und gesundheitsbezogene Lebensqualität bei Patienten mit Melanom im Stadium III/IV unter Behandlung mit neuen adjuvanten Therapien. JDDG Journal der Deutschen Dermatologischen Gesellschaft. 19(2). 215–222. 2 indexed citations
18.
Reschke, Robin, et al.. (2020). Value of first‐line surgical treatment for classic Kaposi sarcoma and potential use of checkpoint inhibitors. JDDG Journal der Deutschen Dermatologischen Gesellschaft. 18(3). 256–262. 1 indexed citations
19.
Reschke, Robin & Mirjana Ziemer. (2020). Rechallenge with checkpoint inhibitors in metastatic melanoma. JDDG Journal der Deutschen Dermatologischen Gesellschaft. 18(5). 429–436. 20 indexed citations
20.
Reschke, Robin & Mirjana Ziemer. (2020). Re‐Induktion einer Checkpoint‐Inhibitor‐Therapie beim metastasierten Melanom. JDDG Journal der Deutschen Dermatologischen Gesellschaft. 18(5). 429–437. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kentaro Sumida Breakdown of academic impact, for papers by Megumi Aoki Breakdown of academic impact, for papers by Jong Myun Park Breakdown of academic impact, for papers by Asuka Kobayashi Breakdown of academic impact, for papers by Helen Chae Breakdown of academic impact, for papers by Yemsratch T. Akalu Breakdown of academic impact, for papers by Christina Paluskievicz Breakdown of academic impact, for papers by Xuexiao Jin Breakdown of academic impact, for papers by Anniek Zaalberg
Rankless by CCL
2026